What is Syntax Bio?
Syntax Bio is a Chicago, IL-based biotechnology firm co-founded by Ryan Clarke, PhD, and Professor Brad Merrill, PhD, from the University of Illinois at Chicago. The company is dedicated to generating therapeutic-grade cells from stem cells utilizing its innovative Cellgorithm platform. This technology mimics human developmental processes at the epigenetic level, employing a modified CRISPR system to automatically and temporally regulate endogenous genes. The company's focus on preclinical development positions it in a critical growth phase, aiming to translate its platform technology into viable therapeutic solutions.
How much funding has Syntax Bio raised?
Syntax Bio has raised a total of $18.9M across 2 funding rounds:
Seed
$4.5M
Series A
$14.4M
Seed (2021): $4.5M, investors not publicly disclosed
Series A (2026): $14.4M led by Illinois Film Office, Mayo Clinic, Draper Associates, Portal Innovations, Allegis Capital, EGB Capital, Civilization Ventures, Illinois Ventures, LongGame, Mansueto Office, DCVC Management, Illumina Ventures, Exitfund, and Astellas Venture Management
Key Investors in Syntax Bio
Illinois Film Office
The Illinois Department of Commerce and Economic Opportunity (DCEO) provides extensive business support services, including energy assistance, job training, and small business development, with a focus on equity and community growth.
Mayo Clinic
Mayo Clinic is a global nonprofit healthcare organization renowned for its integrated clinical practice, education, and medical research, offering comprehensive services across numerous international locations.
Draper Associates
Draper Associates is a venture capital firm with extensive experience in funding transformative companies in sectors like AI, blockchain, and biotech, focusing on innovative ideas that shape the future.
What's next for Syntax Bio?
With the recent major strategic investment, Syntax Bio is poised to further its research and development efforts, likely focusing on preclinical trials and platform optimization. The substantial enterprise-level funding suggests a strong investor confidence in the company's long-term vision and the potential of its Cellgorithm technology. Future strategic financing rounds may be anticipated as the company progresses towards clinical applications, aiming to solidify its market position in the competitive biotechnology landscape.
See full Syntax Bio company page
